Cancer biomarker research by Elypta
Analysing 2064 samples from Lifelines participants, Elypta was able to demonstrate the potential of GAGomes as metabolic biomarkers for early cancer detection. Plasma and urine GAGomes showed double the stage sensitivity reported by state-of-the-art genomics biomarkers (62% sensitivity to stage I disease at 95% specificity), and predicted the detection of any cancer type with poor prognosis within 18 months with 43% sensitivity.
Dr. Marianna Mirabelli, Director of Clinical Development, Elypta
"The Lifelines cohort study has enabled us at Elypta to study the risk of developing multiple cancer types in a presumed healthy population over time, and enabled us to identify the profiles of glycosaminoglycans as early indicators of cancer several years before clinical diagnosis. We are grateful to Lifelines for the opportunity to push the boundaries of early cancer detection and to ultimately improve patient outcomes."
Background
Elypta is dedicated to advancing the early detection and personalized monotoring of cancer through innovative technologies. The company has developed a cutting-edge, metabolism-based liquid biopsy platform designed to measure a comprehensive panel of glycosaminoglycans (GAGomes). These GAGomes are complex sugar molecules that play a crucial role in various biological processes, including cancer progression. Elypta's liquid biopsy platform leverages the unique metabolic signatures of GAGomes to identify cancer-specific biomarkers. This approach involved analyzing blood and urine samples to detect subtle changes in the levels and structures of glycosaminoglycans, which can indicate the presence of cancer. By focusing on these metabolic biomarkers, Elypta aims to provide a more accurate and non-invasive method for cancer detection compared to traditional biopsy techniques.
Impact for more healthy years
The results of this study show that GAGomes can be considered early indicators of cancer several years prior to clinical diagnosis.